Naglaa H. Shoukry
Professor
Microbiology & Immunology
McGill University
Canada
Biography
Dr. Shoukry obtained her Pharmacy degree from Cairo University (1991) and Ph.D. in Immunology from McGill University (2000). Her postdoctoral research has established the essential and complementary roles of CD8 and CD4 T lymphocytes in resolution and protection from HCV infection. Since joining the Université de Montréal and CRCHUM in 2005, she has established a translational research program focused on studying immunity to HCV in a unique cohort of people who inject drugs in collaboration with Dr. Julie Bruneau. Recently, her research has expanded to studying immunological mechanisms of liver fibrosis progression and development of liver cancer. She has published over 60 articles in high impact journals related to liver immunology and has received multiple awards from the American Liver Foundation, the Canadian Institutes of Health Research (CIHR) and Fonds de recherche du Québec – Santé (FRQS). In June 2014, she was selected to lead the application for the Canadian Network on Hepatitis C (CanHepC) that was funded in 2015 for $4.5 million to establish a pipeline from research to implementation and to improve the lives of Canadians living with hepatitis C.
Research Interest
Hepatitis C virus (HCV) infection affects nearly 3% of the world population. The majority of individuals exposed to the virus become persistently infected and go on to develop chronic liver disease including liver cancer. Despite the recent development of highly effective direct acting antivirals against HCV, it will remain a problem for millions of patients who are not eligible to receive these treatments and who continue to transmit new HCV infections. Hence, the urgent need for an effective prophylactic vaccine to limit HCV transmission. Vaccine development is hampered by our limited understanding of protective immunity against HCV.
Publications
-
Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection. Rodrigo C, Walker MR, Leung P, Eltahla AA, Grebely J, Dore GJ, Applegate T, Page K, Dwivedi S, Bruneau J, Morris MD, Cox AL, Osburn W, Kim AY, Schinkel J, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins M, Luciani F, Lloyd AR, Bull RA.
-
Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration. Morris MD, Shiboski S, Bruneau J, Hahn JA, Hellard M, Prins M, Cox AL, Dore G, Grebely J, Kim AY, Lauer GM, Lloyd A, Rice T, Shoukry N, Maher L, Page K.
-
Type 2 immunity is protective in metabolic disease but exacerbates NAFLD collaboratively with TGF-β. Hart KM, Fabre T, Sciurba JC, Gieseck RL 3rd, Borthwick LA, Vannella KM, Acciani TH, de Queiroz Prado R, Thompson RW, White S, Soucy G, Bilodeau M, Ramalingam TR, Arron JR, Shoukry NH, Wynn TA.
